The abstract is read at the publisher; the summary is JClub's.
SLC25A39 loss in glioblastoma cells depletes mitochondrial glutathione and triggers oxidative damage plus metabolic rewiring, while conferring temozolomide resistance and strong navitoclax sensitivity.
- Why it matters: Hypoxia and phenotypic plasticity contribute to therapy resistance, but how mitochondrial glutathione buffering via SLC25A39 is regulated and whether it creates drug vulnerabilities in glioblastoma is unknown.
- What they did: The study shows SLC25A39 is hypoxia-inducible and HIF-dependent, enriched in hypoxic tumour niches, then tests how its loss affects mitochondrial redox, respiration, and growth, including drug combinations with navitoclax, radiation, and temozolomide.
- The result: SLC25A39-deficient cells grow poorly yet resist temozolomide, and they become markedly sensitive to navitoclax, with increased killing when combined with radiation and temozolomide, supporting SLC25A39 as a stratification marker.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.